<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 168 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page167.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=168">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 168 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 168</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=168"><img src="../thumb/168.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Blood and Haemopoeitic - 8.1 / 8.2                                             2020-04 / 137

                   THE NOAC* YOU AND YOUR PATIENTS CAN RELY ON


                     *NOAC = non-vitamin K oral anticoagulant

       dos.of 270 µg/kg bodyweight in elderly, durat. of home treatm.not to   of infect.agents incl.unknown/emerg. virus. & other pathog.cannot   719320-001: 5 mg/0,4 ml, 10’s, R1 342,95
       exceed 24 hrs., hospital care mandat.if bleed.not kept und.control.,   be totally excl., appropr. vaccinat.(hepatit.A & B) should be consid.   719321-001: 7,5 mg/0,6 ml, 10’s, R2 105,67
       avoid simultan.prothrombin complex.conc.use, limit. exper.with con-  for pts.receiv.reg./repeat.human plasma-deriv. fact.IX concentrats.,   719322-001: 10 mg/0,8 ml, 10’s, R2 807,56
       com.anti-fibrinolyt.treatm., not known if reproduct.capacity in women   controll.Na diet, no clinic. stud.perform.in childr.&lt;12 yrs./prev. untreat.   Dosage: Admin.by SC inj.only.
       affect., childr., monit.fact.VII defic.pts.for antibod./ prothromb. time/  pts., perf.recov.& half-life in childr.6-12 yrs. in order to adjust indiv.dos.,   Treatm.of DVT & PE: Body weight &lt; 50 kg: 5 mg SC 1x dly. Body
       fact.VII anticoag.activ.bef.& aft. ther. admin., antibod.developm.risk.  monit.bld. platelet count closely esp.at init.of treatm.  weight 50-100 kg: 7,5 mg SC 1x dly. Body weight &gt; 100 kg: 10 mg
       OCTANATE, Octapharma [P/S]    TRANIC, Litha [P/S]          SC 1x dly. Cont.treatm.for at least 5 days & until adeq. oral antico-
                                                                  agulat.est.(INR 2-3). Usual treatm.durat.: 5-9 days. Initiate concom.
       Human coagulation factor VIII  Tranexamic acid.            treatm.with vit.K antagon. as soon as poss.(usual.within 72 hrs).
       Indications: Treatm.& prophylax.of bleed.in pts.with haemophilia   Indications: Short-term treatm.of hyphaema, pts. with est.coagu-  Contraindications: Act.maj.bleed., sev.ren. impairm., infect.endo-
       A (congenit.fact.VIII defic.), acquird. fact. VIII defic. &  haemophilia   lopathies undergo.min.surg., dent. extract. in haemophil., heredit.  cardit., pregn.& lactat., body weight less than 50 kg, pts.who have
       with antibod. against fact. VIII   angioneurot.oed., menorrhag.  undergone surg.of the brain/eye/ear or spinal cord or who have injur.
       (S4) POWD.FOR SOL FOR INJ. 36/30.3/0344, 0345, 0346  (S4) TABS, 41/8.1/0223  of the brain/eye/ear or spinal cord., IM admin., safety & effic.in HIT-
       713085-001: 250 IU, 5 ml, R792,86  716276-001: 500 mg, 30, R179,68  type II not form.stud., safety & effic.in paed.pts.not stud.
       713086-001: 500 IU, 10 ml, R1 585,72  Dosage: Traumat.hyphaem: 1-1,5 g 8 hrly.x6-7 days.  Side effects: Post-op wound infects., anaem., bleed., purpura, throm-
       713084-001: 1000 IU, 10 ml, R3 171,43  Est.coagulopathy pts.undergo.min.surg: Cerv. conisat: 1-1,5 g   bocytopen., thrombocythaem., abnorm.platel., coagulat. disords., al-
       Dosage: Admin.slow.IV(not more than 2 - 3 ml/ min.), measur.to treat   8-12 hrly for 12 days post-op.  lerg.reacts., hypokalaem., insomn., headache, anx., confus., dizzin.,
       anaphylax.must be avail., dos.& durat.of substitut.ther.depends on   Dent.proced: 25 mg/kg 2 hrs pre-op with Factor VIII and Factor IX   somnol., vertigo, GI disturbs., hypotens., dyspn., cough., abnorm. liv.
       severity of disord.of haemostat.funct./locat.and extent of bleed., type   then 25 mg/kg 3-4 xdly for 6-8  days post-op.  funct.test, incr.hepat.enzym., bilirubinaem., UTI, urin.retent., rash,
       of surg.& pt.clinic.condit.   Heredit.angioneurot.oed: 1-1,5 g 2-3 xdly for some days or con-  prurit., loc.bull.erupt., wound secret., oed., periph.oed., fev., inj.site
       Refer to prod.lit.for dos.calc.  tin.in some.              reacts., chest /leg pain, fatig., flush., syncope.
       If expect.fact.VIII activity plasma lev.not attained/ bleed.not controll.  Menorrhag: 2-3 tabs.3-4 xdly giv.at onset of bleed. & durat.of per.  Warnings and special precautions: Epidur./ spin. haematom.
       with appropr.dos. perform assay to determ.pres.of fact.VIII inhibit., If   Contraindications: Massive upper urin.tract. haemorrh..to reduc.  result.in long-term/perman. paralys. cannot be excl.with concurr.use
       inhibit.is pres. at levels &lt; 10 BU/ml: Admin. addit.human coagulat.   ureter.obstruct.risk, thrombot. tenden., col.vis.disord., thrombophle-  and spin./ epidur. anaesthes or spin.punct., epidur./spin. haematoma
       fact. VIII may neutral.the inhibit.  bit., imp.liv. funct., subarachn.bleed.  risk high.with post-op use of indwell. epidur. catheters or concom.
       If inhibit.titr.&gt; 10 BU/with high anamnest. respons.: Consid.use   Side effects: Less freq: N&V, diarrh., trans. colour vis. disturbs.,   meds.affect. haemostas incl.NSAID’s/ acetylsalicyl.acid & other
       of (activat.)prothromb. complex conc.(PCC)/recombin.activat.fact.  thrombot.complicat.  platel. inhibit., remove epidur.& spin.cathet.at end.of surg. proced.,
       VII (rFVIIa) preps.           Warnings and special precautions: Ren.funct. impairm., discont.  not interchang.unit for unit with hepar./low molecul.weight hepar./
       Contraindications: Do not use unless fact.VIII defic.has been   if col.vis.disturbs.exper., concom. anticoag.with thrombo-embol.dis.  heparinoids, not recom.prior/dur.PCI in STEMI pts. undergo. prim.
       verif., do not use to correct fact.IX defic., not for monother.of dis-  hist., reg. ophthalm. exam.incl.vis.acuity/colour vis./eye grounds/  PCI for reperfus., not recom.as sole anticoag. dur.PCI in UA/NSTEMI
       seminat.IV coagulat. (DIC)., childr.&lt;6 yrs., pregn.& lactat., do not   vis.fields advis.bef.start.& dur.treatm.if long. than sev.days also liv.  & STEMI pts. undergo.non-prim.PCI, limit.data on UFH use dur. non-
       mix. with other.meds.         funct.test., concom. meds. with act.on haemostas., safety in pregn.  prim.PCI in Arixtra treat.pts., incr.risk of guid. catheter thrombus in
       Side effects: Hypersens.reacts., anaphylact. shock, fev., fact.VIII   not est., pass. into breast milk.  pts.treat.solely with Arixtra for anticoagulat.dur.PCI, plasma clear.
       antibods.in bld.              Interactions: Potent.thrombus format. poss. incr. with concom.oes-  decr.with sev. of ren.impairm., maj bleed.episod.& VTE risk incr. with
       Warnings and special precautions: Discont.if allerg./anaphy-  trog., antagonis.by thrombolyt.  ren.impairm., assess ren.funct.period. dur. treatm. & discont.immed.
       lact.reacts.occur, implem.std.med. treatm. in case of shock, careful.  if sev.ren.impairm./ labile ren.funct.develops, anticoag.eff.persists aft.
       monitor.for developm. of inhibit.antibod.by appropr.clinic. observat.   discont., elderly/pts.und.50 kg, sev.hepat.impairm., condits./ concom.
       & lab.tests., exam.pt.for pres.of fact. VIII inhibits.if allerg.reacts.oc-  meds.with incr.haemorrh.risk, strict. adher.to tim.of 1  dos., admin.
                                                                                         st
       cur as pts.with fact. VIII inhibits.potent.at incr.risk of anaphylax.with  8.2  Anticoagulants  bef.6 hrs.post surg. has been assoc.with incr.bleed.risk, discont. in
       subseq. treatm.with fact.VIII., first fact.VIII admin. should be per-  unexpect.changes in coagulat.paramet./maj. bleed. occurs/platel.
       form.und.med.supervis. where appropr.med.care for allerg.reacts.  ELIQUIS (MDR Listing)  count falls bel.100 000/mm , mod. ren.impairm., pts.with hist of HIT,
                                                                              3
       avail., transmis. of infect.agents incl.unknown/emerg. virus. & other   PRADAXA (MDR Listing)  monit.clos. for any degree of thrombocytopen., needle shield of pre-
       pathog.cannot be totally excl., consid. appropr. vaccinat. (hepatit.A   ARIXTRA, Aspen Pharmacare [P/S]  fil.syr.may cont.dry natur.latex rubber & has potent.to cause allerg.
       & B) for pts. receiv. reg./repeat.human plasma-deriv.fact.VIII prods.  Fondaparinux sod.  reacts.in latex sensit.indivs., pt. may self-inj.only if med.practit.de-
       OCTANINE F, Octapharma [P/S]  Indications: Reduct.risk of ven.thromboembol. events (VTE) in pts.  term.aprop.& with med.follow-up as necess.
       Human coagulation factor IX 250 (500)(1000) IU, heparin 25 (50)  undergo.maj.orthopaed.surg.of low.limbs (e.g.hip fract./maj.knee   ASPEN WARFARIN, (Aspen Pharmacare: Pharma)
       (100) IU/vial                 /hip replacem. surg.)/ pts undergo.abdom.surg who are at risk of   Pharmacare [P/S]
       Indications: Treatm.& prophylax.of bleed.in pts. with haemophilia   thromboembol.complicats., treatm.of unstable ang./non-ST segment   Warfarin sodium clathrate equiv.to warfarin sod.
       B (congenit.fact.IX defic.)   elevation MI (UA/NSTEMI) ac.coron.syndr.for prev.of death/MI & re-  Indications: Prevent.& managem.of DVT & pulm. embol. Prevent.of
       (S4) POWD.& SOLV.FOR SOL FOR INJ. 37/30.3/0645, 0646, 0647  fract. ischaem., treatm.of ST segment elevation MI (STEMI) ac.coron.  thromboembol.in atrial fibrillat., prosthet.heart valves, post MI.treatm.
       713054-001: 250/25 IU, 5 ml, R919,63  syndr.for prev.of death & MI in pts. manag.with thrombolyt./who init.  of trans. ischaem.attacks.
       713100-001: 500/50 IU, 5 ml, R1 839,25  to receive no other form of reperfus.ther.  (S4) TABS. H/8.2/0742.
       713099-001: 1000/100 IU, 10 ml, R3 678,50  (S4) SOL FOR INJ, 36/8.2/0364. 2,5 mg/0,5 ml  778362-019: 5 mg, 100, R213,24
       Dosage: Admin.slowly (not more than 2 - 3 ml/ min.) & IV, meas.to   709669-001: 10 x prefill.syr., R1 151,93  Dosage: Individ.dos. PT measurem.should be carried out bef.treatm.,
       treat anaphylax.must be avail., dos.& durat.of substitut.ther.depends   Dosage: Admin.by SC/IV inj. Admin.init.dos.6 hrs. follow.surg.  on 2  & 3  days of treatm. and then on alt.days until the maint.dos.
                                                                    nd
                                                                       rd
       on severity of fact.IX defic./locat./extent of bleed.& pt clinic. condit.  clos. provid.haemostas.est. Admin.bef. 6 hrs.has been assoc.with   is est. Thereaft.monit.mnthly.
       Refer to prod.lit.for dos.calc.  incr.bleed.risk. Do not mix.with other meds. See prod.lit.for detail.  Init.dos.usual.within range of 10-15 mg dly.x3 days. Maint. dos.range
       If expect.fact.IX activity plasma lev.not attained/ bleed. not controll.  admin. det.  from 2-10 mg dly. Give dos. at same time each day.
       with appropr.dos.perform assay to determ.pres.of fact.IX inhibit. If in-  Orthopaed./abdom.surg: Recomm.dos: 2,5 mg SC once dly.post-op.   Contraindications: Haemorrhag.states, pept. ulc., other GI dis.in-
       hibit.is present.at levels &lt; 10 BU/ml: Admin.of addit. coagulat. fact.  for at least 7 ± 2 days and for as long as VTE risk persists.  volv.bleed., condits.involv. bleed. from resp./genito-urin.tract., sev.
       IX may neutral.the inhibit.   Unstable ang./non-ST segment elevation MI (UA/NSTEMI):   wounds (incl. surg.), infect.endocardit., imp.liv./kidn.funct., hyper-
       If inhibit.titr.&gt; 10 BU/with high anamnest. response: consid.use   Recomm.dos: 2,5 mg SC once dly. Init.treatm.as soon as poss.fol-  tens., cerebrovasc.haemorrh., cerebr./aort. aneurysm., pericardit.,
       of (activat.)prothromb. complex concentr (PCC)./activat.fact.VII   low.diagn. & contin. for upto 8 days/hosp.discharge. If pt.undergoes   pericard.effus., recent/ contemplat. neuro/ophthal.surg., polyarthrit.,
       (rFVIIa) preps.               PCI while on ARIXTRA admin.UFH dur. PCI as per std. pract.taking   vit.C defic., maj.reg.block.anaesth., inadeq.lab.facilit./ poor pt.co-
       Contraindications: Known allergy relat.reduct. of thrombocyt.dur.  pt’s potent. risk of bleed.incl.time since last dos.into acc. Timing of   op., breastfeed., threaten.abort., pregn. (recog.teratogen.), concom.
       heparin treatm.(heparin induc. thrombocytopen.[HIT] type II), pregn.&   restart.SC treat. aft. sheath remov.should be based on clinic. judge-  NSAID, childr.young. than 18 yrs.
       lactat., do not mix.with other meds., childr.&lt;6 yrs.  ment., in UA/NSTEMI clinic.trial treatm.was not restart.within 2 hrs.   Side effects: Haemorrh., skin necros., purple toe syndr., alopec., fev.,
       Side effects: Hypersens.reacts., anaphylact. shock, thrombo-embol.  aft.sheath remov. Do not giv. dur.24 hrs.prior to CABG surg. May be   N&V, diarrh., hypersens.& skin reacts.
       event, nephrot.syndr., heparin induc.thrombocytopen., pyrex., anti-  re-start. 48 hrs.post-op.  Special precautions: No abrupt.cessat., elderly, vit.K defic., hyper-
       fact. IX antibody positive    Treatm.of ST segment elevation MI (STEMI): Recomm.dos:   thyroid., indiv.dos.with reg. Prothrombin time determinat., close liai-
                                              st
       Warnings and special precautions: Discont.if sympts.of hyper-  2,5 mg once dly.with 1  dos.admin. IV & subseq.dos.SC. Init.treatm.as   son betw. drs.in pts.undergo.surg./dent.proced., prolong. diet. defic.,
       sens.occur, implem.std.medic. treatm. in case of shock, monit.aft.re-  soon as poss. follow. diagn. & contin.for upto 8 days/hosp. discharge.   infect.dis., intestin.flora disturbs., sprue, antibiot.ther., polycythaem.
       peat treatm. for developm.of neutralis.antibod.using appropr. biologic.   If pt.undergoes non-prim.PCI while on ARIXTRA admin.UFH dur. PCI   vera, vasculit., sev. diab., allerg./anaphylact.disords., good pt. instruct,
       tests., eval.pt.for pres.of fact.IX inhibits. if allerg. reacts.occur as pts.  as per std pract. taking pt’s potent.risk of bleed.incl.time since last   poss.prothromb.time incr.in: carcinoma, collag.dis., CHF, diarrh., elev.
       with fact.IX inhibits. potent. at incr.risk of anaphylax.with subseq. chal-  dos. into acc. Timing of restart.SC treatm.aft. sheath remov.should   temp., hepat. disords., infect.hepatit., jaund., poor nutrit.state, poss.
       leng with fact. IX., init.admin.should be perform. und.medic.supervis.  be based on clinic. judgement., in STEMI clinic.trial treatm.was not   decr. prothromb.time in: diab.mellit., oed., heredit.resist. to warfar.
       where appropr.med. care for allerg.reacts.avail., init.clin.surveill.for   restart. within 3 hrs. aft.sheath remov.,do not giv. dur.24 hrs.prior to   ther., hypothyroid., hyperlipaem., lact.intol.
       early signs of thrombot.& consumpt.coagulopathy with appropr.bi-  CABG surg. May be re-start.48 hrs.post-op.  Drug interactions: Agents that enhance the anticoag. eff: sulphon-
       olog.test. & weigh.benef:risk in liv. dis./ post-op.pts./neonates/pts at   (S4) PRE-FILLED SYR, 43/8.2/0021, 0022, 0023. 12,5 mg/ml  am., sulphonylurea-type antidiabet. agents, clofibrate, cimetidine,
       risk of thrombot. phenom./disseminat.IV coagulat (DIC), consid. risk   Indications: Treatm.of ac.deep vein thrombos. (DVT) & ac.pulmon.  phenylbutaz. & other pyrazolones, anabol.steroids, sulphinpyraz.,
       of CVAD-relat, complicats.incl.loc. infects./ bacteraem./cathet.site   embol.(PE) except in haemodynamic. unstab.pts.req.thrombolys./  aspir.& other NSAID’s, thyroid hormon., disulfiram & amiodar., agents
       thrombos.if centr. venous access device (CVAD) is reqd., transmis.   pulm. embolect.  that dimin. the anticoag.eff: barbitur., rifampic.& glutethimide., Vit.K is
                            S4 Pradaxa ® . 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131. S4 Pradaxa ® . 150 mg. Each capsule contains 150 mg of dabigatran
                            etexilate base (as mesilate salt). Reg. No. 45/8.2/0162. For full prescribing information refer to the professional information approved by the Regulatory Authority.
                            Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100406. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page167.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>
             </td>
             <td width="35%"><a href="page169.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page169.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
